New drug hopes to halt liver damage in MASH patients

NCT ID NCT07221188

Recruiting now Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This phase 3 trial tests a drug called efimosfermin alfa in 1250 adults with MASH (a fatty liver disease) and moderate liver scarring. The main goal is to check safety and side effects. Participants will receive either the drug or a placebo, and researchers will monitor liver health over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Efimosfermin Alfa
What this could lead to: If successful, this could point toward a treatment that slows or stops liver damage in people with MASH and fibrosis.
What could go wrong: This is an early-stage safety trial, so it may not prove the drug works. Side effects or lack of benefit could stop development.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-ALCOHOLIC FATTY LIVER DISEASE

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

Arcadia, California, 91006, United States
GSK Investigational Site
RECRUITING

Covina, California, 91723, United States
GSK Investigational Site
RECRUITING

Los Angeles, California, 90057, United States
GSK Investigational Site
RECRUITING

San Diego, California, 92120, United States
GSK Investigational Site
RECRUITING

Santa Maria, California, 93458, United States
GSK Investigational Site
RECRUITING

Van Nuys, California, 91405, United States
GSK Investigational Site
RECRUITING

Boynton Beach, Florida, 33435, United States
GSK Investigational Site
RECRUITING

Cape Coral, Florida, 33914, United States
GSK Investigational Site
RECRUITING

Doral, Florida, 33016, United States
GSK Investigational Site
RECRUITING

Hialeah, Florida, 33016, United States
GSK Investigational Site
RECRUITING

Homestead, Florida, 33033, United States
GSK Investigational Site
RECRUITING

Inverness, Florida, 34452, United States
GSK Investigational Site
RECRUITING

Jacksonville, Florida, 32216, United States
GSK Investigational Site
RECRUITING

Kissimmee, Florida, 34744, United States
GSK Investigational Site
RECRUITING

Lakeland, Florida, 33803, United States
GSK Investigational Site
RECRUITING

Maitland, Florida, 32751, United States
GSK Investigational Site
RECRUITING

Miami, Florida, 33135, United States
GSK Investigational Site
RECRUITING

Miami, Florida, 33155, United States
GSK Investigational Site
RECRUITING

Miami, Florida, 33156, United States
GSK Investigational Site
RECRUITING

Miami, Florida, 33173, United States
GSK Investigational Site
RECRUITING

Miami, Florida, 33184, United States
GSK Investigational Site
RECRUITING

Miami Lakes, Florida, 33014, United States
GSK Investigational Site
RECRUITING

Ocala, Florida, 34471, United States
GSK Investigational Site
RECRUITING

Palmetto Bay, Florida, 33157, United States
GSK Investigational Site
RECRUITING

Sarasota, Florida, 34201, United States
GSK Investigational Site
RECRUITING

Topeka, Kansas, 66606, United States
GSK Investigational Site
RECRUITING

Marrero, Louisiana, 70072, United States
GSK Investigational Site
RECRUITING

Springfield, Missouri, 62703, United States
GSK Investigational Site
RECRUITING

St Louis, Missouri, 63141, United States
GSK Investigational Site
RECRUITING

Jersey City, New Jersey, 07059, United States
GSK Investigational Site
RECRUITING

East Syracuse, New York, 13057, United States
GSK Investigational Site
RECRUITING

New York, New York, 10036, United States
GSK Investigational Site
RECRUITING

Morehead City, North Carolina, 28557, United States
GSK Investigational Site
RECRUITING

Akron, Ohio, 44320, United States
GSK Investigational Site
RECRUITING

Springboro, Ohio, 45066, United States
GSK Investigational Site
RECRUITING

Chattanooga, Tennessee, 37421, United States
GSK Investigational Site
RECRUITING

Austin, Texas, 78745, United States
GSK Investigational Site
RECRUITING

Austin, Texas, 78759, United States
GSK Investigational Site
RECRUITING

Brownsville, Texas, 78526, United States
GSK Investigational Site
RECRUITING

Dallas, Texas, 75243, United States
GSK Investigational Site
RECRUITING

DeSoto, Texas, 75115, United States
GSK Investigational Site
RECRUITING

Richmond, Texas, 77406, United States
GSK Investigational Site
RECRUITING

San Antonio, Texas, 78209, United States
GSK Investigational Site
RECRUITING

San Antonio, Texas, 78215, United States
GSK Investigational Site
RECRUITING

San Antonio, Texas, 78229, United States
GSK Investigational Site
RECRUITING

Seabrook, Texas, 77586, United States
GSK Investigational Site
RECRUITING

Tomball, Texas, 77375, United States
GSK Investigational Site
RECRUITING

Waco, Texas, 76710, United States
GSK Investigational Site
RECRUITING

Waco, Texas, 76712, United States
GSK Investigational Site
RECRUITING

West Jordan, Utah, 84088, United States
GSK Investigational Site
RECRUITING

Manassas, Virginia, 20110, United States
GSK Investigational Site
RECRUITING

Seattle, Washington, 98105, United States
GSK Investigational Site
RECRUITING

Pokfulam, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.